When was Mission Therapeutics founded?

Mission Therapeutics was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is Mission Therapeutics located?

Mission Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at Babraham Hall, Babraham, Cambridge, CB22 3AT.

Who is the current CEO of Mission Therapeutics?

Anker Lundemose of Mission Therapeutics.

Which legal entities is Mission Therapeutics associated with?

Mission Therapeutics is associated with Mission Therapeutics Limited.

How many employees does Mission Therapeutics have?

As of Aug 31, 2026, the latest employee count at Mission Therapeutics is 11.

Is Mission Therapeutics a funded company?

Mission Therapeutics is a funded company, having raised a total of $192M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 24, 2011.

How much is Mission Therapeutics worth?

The latest valuation of Mission Therapeutics is $***** as of Jan 31, 2021.

When was the latest funding round of Mission Therapeutics?

Mission Therapeutics' latest funding was a $***** Series D round on Oct 15, 2025, with participation from 6 investors.

What is the annual revenue of Mission Therapeutics?

Annual revenue of Mission Therapeutics is between $1M and $10M as on Dec 31, 2016

Where does Mission Therapeutics rank among its competitors?

Mission Therapeutics ranks 9th amongst 505 active competitors, of which 179 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Mission Therapeutics?

Mission Therapeutics' top competitors include Denali Therapeutics, Fulcrum Therapeutics and AskBio. Among them, Alchemab secured the most recent funding round in July, 2026.

Mission Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of small molecule inhibitors targeting specific disease associated enzymes. These therapeutic candidates focus on the regulation of cellular quality control processes to address neurodegenerative conditions, heart disease, kidney disease, and fibrosis. The research centers on the modulation of protein degradation pathways to influence disease progression.

Website: missiontherapeutics.com
Social
Email ID: *****@missiontherapeutics.com
Phone Number: +44 **********
Registered Address: Babraham Hall, Babraham, Cambridge, CB22 3AT

Key Metrics

Founded Year

2011

Location

Cambridge, United Kingdom

Stage

Series D

Total Funding

$192M in 9 rounds

Latest Funding Round

Series D, Oct 15, 2025, $*****

Post Money Valuation

$***** as on Jan 31, 2021

Investors

Sofinnova Partners & 47 more

Ranked

9^th among 505 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2016

Employee Count

11 as on Aug 31, 2026

Similar Companies

Denali Therapeutics & 617 more

View Mission Therapeutics' full profile

Mission Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Mission Therapeutics Limited CIN: 7630933 , Germany, Active	May 10, 2011	$1M - $10M (As on Dec 31, 2016)	30 (As on Dec 31, 2024)

Mission Therapeutics has raised a total funding of $192M over 9 rounds. Its first funding round was on Aug 24, 2011. Its latest funding round was a Series D round on Oct 15, 2025 for $*****. 6 investors participated in its latest round. Mission Therapeutics has 16 institutional investors and 32 angel investors.

Here is the list of recent funding rounds of Mission Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 15, 2025	2704700	Series D	3015961	5483019	6812636	4296240
Jul 02, 2024	5343447	Grant (prize money)	7083014	8115113	5616404	The Michael J. Fox Foundation & 1 more
Mar 14, 2024	2058662	Series D	1671401	5452914	Rosetta Capital	Pfizer Venture Investments & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Mission Therapeutics's funding rounds and investors

The founders of Mission Therapeutics are Niall Martin, Xavier Jacq and Keith Menear. Anker Lundemose is the CEO of Mission Therapeutics.

Here are the details of Mission Therapeutics' key team members:

Niall Martin: Former Co-Founder of Mission Therapeutics.
Xavier Jacq: Former Co-Founder of Mission Therapeutics.
Keith Menear: Co-Founder of Mission Therapeutics.
Anker Lundemose: CEO of Mission Therapeutics.
Contact Info: 1 email address

Mission Therapeutics' Board of Directors

Mission Therapeutics's board has 7 active members. Denis Patrick and Anker Lundemose are part of team and Matthew James Foy, Carole Nuechterlein, James Summers, Graziano Seghezzi and Jonathan Hepple are independent board members.

Here is the list of Mission Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
vt{boxu	Team	-	Current	2y 3m
Denis Patrick	Investor	Pfizer Venture Investments	Current	7y 4m
Matthew James Foy	Independent board member	-	Current	3y 8m
{adlnnf	Independent board member	-	Current	9y 4m
yucybvj	Independent board member	-	Current	7y 5m
nrlmtk{	Independent board member	-	Current	9y 1m
keaxtgd	Independent board member	-	Current	7y 3m

View details of Mission Therapeutics's Founder profiles and Board Members

Mission Therapeutics' employee count trend

Mission Therapeutics has 11 employees as of Aug 26. Here is Mission Therapeutics's employee count trend over the years:

Employee count trend for Mission Therapeutics

Uncover Mission Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mission Therapeutics include Denali Therapeutics, Fulcrum Therapeutics and AskBio. Here is the list of Top 10 competitors of Mission Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
3rd	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
5th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
8th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
9th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Rosetta Capital, Roche Enterprises & 46 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100